What is Esphera SynBio?
Esphera SynBio is a biotechnology company focused on pioneering novel therapeutic applications through synthetic biology. Their lead platform technology involves the in vivo modification of tumor cells. Specifically, Esphera SynBio aims to transform typically protumourigenic and immunosuppressive tumor-derived exosomes into immunostimulatory, antigen-bearing modifiers of the tumor microenvironment (TME). This approach also facilitates the development of bespoke, patient-specific cancer vaccines, positioning the company at the forefront of personalized oncology.
How much funding has Esphera SynBio raised?
Esphera SynBio has raised a total of $2M across 1 funding round:
Angel/Seed
$2M
Angel/Seed (2025): $2M, investors not publicly disclosed
What's next for Esphera SynBio?
The recent major strategic investment signals a pivotal growth phase for Esphera SynBio, likely enabling the company to advance its platform technology through preclinical and clinical development. This backing is expected to accelerate the optimization of their exosome modification process and the scaling of their patient-specific cancer vaccine initiatives. Strategic partnerships and further R&D will be crucial as Esphera SynBio navigates the complex landscape of cancer therapeutics and aims to translate its innovative synthetic biology platform into tangible patient benefits.
See full Esphera SynBio company page
